Cardiorenalmetabolic

The ESC's 2026 heart failure guidelines overhaul HF classification, rename therapy categories, and add a new HFpEF recommendation.

The first study of its kind links nighttime light exposure to structural heart changes among over 11,000 adults followed for 3 years.

Cleveland heart failure experts discuss the new HFpEF pathway, CKM screening gaps, and drug access barriers.

A random survival forest model trained on 850 patients outperformed the Mayo Clinic and National Amyloidosis Centre staging systems for ATTR-CM.

PVI for intermittent claudication was associated with more than double the rate of major adverse limb events and higher costs of care.

Late-breaking HELIOS-B subgroup data show mortality and CV benefits held regardless of baseline tafamidis use, per results at ESC Congress 2026.

Keith Bellovich, DO, of Strive Health, discusses how the new CKM guideline unifies cardiology, nephrology, and endocrinology care.

Five-year EXPLORER-LTE data show sustained LVOT gradient reductions and NYHA class improvements in patients with obstructive HCM.

A VESALIUS-CV analysis found a 20% reduction in all-cause death with evolocumab in patients without prior MI or stroke, emerging after 1.5 years.

FUSION trial data published show FFRCT added to CCTA safely cut unnecessary catheterizations.

Tirzepatide is now approved to lower cardiovascular death, heart attack, or stroke risk in adults with type 2 diabetes.

The phase 4 study will track serum transthyretin and other biomarkers in 50 adults with ATTR-CM switching from tafamidis to acoramidis over 6 months.

A study shows mobile integrated health was well received by patients and clinicians despite barriers to broader implementation.

Fix cardiorenalmetabolic care gaps: define ownership, task-shift screening, boost uACR testing, and tackle obesity-driven equity barriers.

A secondary analysis of the HELIOS-B trial found that worse left atrial strain was associated with higher risks of mortality and cardiovascular events.

Frequent adolescent sexual assault and discrimination in employment, housing, and police interactions was associated with higher heart failure risk.

Experts discuss why patients with HFmrEF/HFpEF still receive less urgent, less standardized care than those with reduced ejection fraction.

New hypertension drugs cost over $800,000 per QALY vs generics, well above cost-effectiveness limits, ICER's draft report finds.

Most Medicare beneficiaries with ATTR-CM waited more than 6 months for diagnosis after heart failure onset, with longer delays among women.

Although new guidelines call for universal screening, most Americans with elevated Lp(a) still don't know their number.

All from July, these 5 novel therapeutics each claimed a “first” in their category.

A new AHA scientific statement defines pediatric cardiogenic shock and proposes a 5-stage classification to guide diagnosis, monitoring, and escalation of care.

Researchers found no evidence that cooling beyond 6 hours at 33°C improved neurological outcomes in comatose survivors of out-of-hospital cardiac arrest.

A study of more than 270,000 patients with HF found a U-shaped link between ventricular size and mortality risk.

An FDA committee voted 9-3 that available data did not provide substantial evidence of effectiveness for deramiocel in DMD.